Genitourinary tumours, non-prostate 1

LBA27 

Erdafitinib (ERDA) or ERDA Plus Cetrelimab (CET) for Patients With Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa): First Phase (Ph) 2 Results From the NORSE Study

T.B. Powles, et al.

Conclusions

ERDA + CET showed clinically meaningful responses in cis-ineligible patients with 1L mUC and FGFRa. Safety was generally consistent with ERDA alone. Enrollment is ongoing.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA27.html.pdf

651O 

Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

S. Sadeghi, et al.

Conclusions

B4 + P is well tolerated and may have synergistic efficacy in mUC. B2 was expressed in the majority of pts and predicted for improved tx outcome.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/651O.html.pdf

652O 

Dose dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin (dd-MVAC) or Gemcitabine and Cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): results of the GETUG/AFU VESPER V05 phase III trial

C. Pfister, et al.

Conclusions

In the VESPER phase III trial, we reported a benefit on PFS at 3 years for the dd-MVAC arm. In the neoadjuvant group, a better bladder tumour local control with a significant improvement on PFS at 3 years were observed in the dd-MVAC arm.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/652O.html.pdf